Wednesday January 17th 2018

Systematic review of efficacy of TENS for management of central pain in people with multiple sclerosis

Conclusion TENS is a safe and effective non-pharmacological alternative in the management of central pain in people living with MS. TENS intervention to address CP is desirable. (Source: Multiple Sclerosis and Related Disorders)

See original article here: 

Systematic review of efficacy of TENS for management of central pain in people with multiple sclerosis

Leave a Comment

More from category

Study shows high-salt diet causes dementia in mice
Study shows high-salt diet causes dementia in mice

A high-salt diet reduces resting blood flow to the brain and causes dementia in mice, according to a new study by [Read More]

What you should know about neurosarcoidosis
What you should know about neurosarcoidosis

A look at neurosarcoidosis, an inflammatory disease that can affect most organs in the body. Included is detail on [Read More]

Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…
Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…

Multiple sclerosis (MS) is a neuroinflammatory condition characterized by chronic dysregulation of immune responses [Read More]

Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity
Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity

Here's what we selected for you today: NEJM Clinical Practice Center: Review: A number of interventions to modify the [Read More]

FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS
FDA Denies Health Claim for Vitamin D to Prevent MS FDA Denies Health Claim for Vitamin D to Prevent MS

The FDA responded to a petition, saying that after reviewing the evidence, there is no basis for the claim that vitamin [Read More]